MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Leucine-rich repeat kinase 2(LRRK2)"

  • 2019 International Congress

    Parkinson’s disease patients with both GBA and LRRK2 mutations are phenotypically similar to LRRK2 – a possible protective effect?

    N. Omer, A. Thaler, L. Goldstein, A. Orr-Urtreger, M. Gana Weisz, O. Goldstein, D. Cohen Avinoam, M. Kestenbaum, M. Lioti, S. John, J. Cederbaum, A. Mirelman, N. Giladi (Tel Aviv, Israel)

    Objective: To compare the phenotype of patients with Parkinson's disease (PD) who carry dual mutation in both LRRK2 and GBA genes with patients with PD…
  • 2019 International Congress

    Assessing the response to Levodopa/carbidopa intestinal gel infusion based on genetic status

    A. Thaler, V. Livneh, A. Hillel, H. Strauss, G. Yahalom, H. Shabtai, A. Migirov Senderovich, S. Israeli-Korn, T. Fay-Carmon, N. Giladi, S. Hassin Baer, T. Gurevich (Ramat Gan, Israel)

    Objective: The aim of this study was to characterize patients with Parkinson's disease (PD) on Levodopa/carbidopa intestinal gel infusion (LCIG) treatment based on their genetic…
  • 2019 International Congress

    Longitudinal CSF-profile and brain pathology mirrors clinical course of LRRK2-Related Parkinson’s Disease

    I. Wurster, S. Lerche, I. Lachmann, M. Neumann, T. Gasser, K. Brockmann (Tübingen, Germany)

    Objective: Do clinical cognitive profiles and CSF characterisitcs of Abeta1_42, total-tau, phospho-tau and alpha-synuclein during lifetime correspond to histopathological findings post-mortem in LRKK2-associated Parkinson’s disease…
  • 2019 International Congress

    Increased level of a lysosomal phospholipid, BMP, in urine of LRRK2 G2019S mutation carriers with or without Parkinson’s disease: implications for therapeutic development

    R. Alcalay, F. Hsieh, S. Padmanabhan, M. Baptista, C. Kehow, S. Narayan, A. Boehme, K. Merchant (Cambridge, MA, USA)

    Objective: To study alterations in urinary phospholipids as biomarkers of LRRK2 mutations and Parkinson’s disease (PD) status. Background: LRRK2 mutations are a common cause of…
  • 2019 International Congress

    Investigating the cellular role of LRRK2 in the immune system

    I. Nazish, R. Bandopadhyay (London, United Kingdom)

    Objective: The objective of this project is to investigate the effect of Leucine Rich-Repeat Kinase 2 (LRRK2) dysfunction in the signalling mechanisms in macrophages and…
  • 2019 International Congress

    Structural connectivity changes in G2019S-LRRK2 gene mutation carriers without manifest Parkinson’s disease

    G. Pagano, P. Vickers, J. Schulz, H. Wilson, M. Politis (London, United Kingdom)

    Objective: We hypothesised that abnormal sprouting of serotonergic terminals in the hypothalamus may lead to abnormal structural connectivity, which can be measured with diffusion tensor…
  • 2019 International Congress

    Genotype influences circuit compensation in Parkinson’s disease

    K. Schindlbeck, A. Vo, N. Nguyen, C. Tang, M. Niethammer, V. Dhawan, V. Brandt, R. Saunders-Pullman, S. Bressman, D. Eidelberg (Manhasset, NY, USA)

    Objective: This study investigates differences in brain network organization in patients with Parkinson’s disease (PD) with genetic risk factors relative to sporadic PD patients and…
  • 2018 International Congress

    PD associated with GBA and LRRK2 mutations: Genotype-phenotype correlation

    V. Livneh, G. Yahalom, L. Greenbaum, S. Israeli-Korn, T. Fay-Karmon, S. Hassin, Z. Gan Or (Ramat Gan, Israel)

    Objective: To study differences in disease characteristics in PD associated with 1 or 2 mutations in the most common PD-associated genes in the Ashkenazi Jewish…
  • 2018 International Congress

    Activation of chaperone-mediated autophagy reduces oligomeric alpha-synuclein accumulation in LRRK2(R1441G) knockin mouse model of Parkinson’s disease (PD)

    P.W.L. Ho, C.S.C. Lam, M.C.T. Leung, S.Y.Y. Pang, H.F. Liu, L. Li, M.H.W. Kung, D. Ramsden, SL. Ho (Hong Kong)

    Objective: To determine age-dependent accumulation of oligomeric alpha-synuclein in the brain of aged LRRK2(R1441G) knockin mice; and to explore whether activation of chaperone-mediated autophagy (CMA)…
  • 2018 International Congress

    Application of the Movement Disorder Society Prodromal Criteria in healthy G2019S-LRRK2 carriers

    A. Mirelman, R. Saunders-Pullman, R. Alcalay, S. Shustak, A. Thaler, B. Cohen, A. Hillel, T. Gurevich, D. Raymond, H. Mejia-Santana, L. Ozelius, L. Clark, M. Gana-Weisz, A. Bar-Shira, A. Orr-Urtreger, S. Bressman, K. Marder, N. Giladi (Tel Aviv, Israel)

    Objective: To evaluate the MDS prodromal criteria in first-degree relatives of Ashkenazi Jewish G2019S-LRRK2 PD patients, who are considered a population at risk for developing…
  • « Previous Page
  • 1
  • …
  • 12
  • 13
  • 14
  • 15
  • 16
  • …
  • 19
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • AI-Powered Detection of Freezing of Gait Using Wearable Sensor Data in Patients with Parkinson’s Disease
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • #28953 (not found)
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • VIT-D and Tics Movement Disorder
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley